Zelgen(SH:688266) 2 1 Shi Ji Jing Ji Bao Dao·2025-06-05 14:06Group 1 - Yara International's supervisor Peng Zhiyun is under investigation for insider trading, which is unrelated to the company's daily operations [2] - The company is operating normally despite the investigation, and Peng has applied to resign from his position [2] Group 2 - Fulin Precision's subsidiary Jiangxi Shenghua signed a supplementary agreement with CATL to increase production capacity to 160,000 tons/year in Jiangxi and 200,000 tons/year in Sichuan [3] - The agreement ensures that CATL will prioritize its demand from Jiangxi Shenghua and commit to purchasing at least 80% of the promised capacity annually [3] - This partnership is expected to enhance the competitiveness and sustainability of Fulin Precision's lithium iron phosphate business [3] Group 3 - Zai Jian Pharmaceutical signed an exclusive market promotion service agreement for recombinant human thyroid-stimulating hormone injection with Merck's Swiss subsidiary, Ares Trading S.A. [3] - The agreement includes a maximum authorization fee of RMB 250 million, with an initial payment of RMB 50 million due within 30 working days after the agreement takes effect [3] - The product is currently in the drug registration application stage [3] Group 4 - Wenta Technology announced that its major shareholder, Wuxi Guolian Integrated Circuit Investment Center, plans to reduce its stake by up to 3%, equating to 37.34 million shares [4] - The reduction will occur between June 27, 2025, and September 26, 2025 [4] Group 5 - Sanofi Guojian's application for a new drug listing for a recombinant anti-IL-1β humanized monoclonal antibody injection has been accepted by the National Medical Products Administration [5] - The drug is intended for the treatment of acute gouty arthritis and has achieved primary efficacy endpoints in Phase III clinical trials [5] Group 6 - Shuyou Shen's product STSP-0601 has been included in the priority review list by the National Medical Products Administration [6] - The product is a Class 1 therapeutic biological product approved for clinical trials for hemophilia A or B patients [7] Group 7 - Ningbo Port expects to complete a container throughput of 4.53 million TEUs in May, representing a year-on-year increase of 7.1% [8] - Wens Foodstuff's pig sales revenue increased by 14.23% year-on-year in May [8] - Dongfeng Motor's cumulative vehicle sales from January to May were 59,859 units, a decrease of 14.45% year-on-year [8]